Novartis to lay off 371 in UK

Share this article:

Novartis is laying off 371 employees at its UK manufacturing site in Horsham. News burbled up on the In the Pipeline blog and was later confirmed by the West Sussex County Times. The company tells the Times that the layoffs are part of a company reorg that is focusing on resource alignment, also known as streamlining and finding efficiencies.

Tuesday's news tracks closely with the company's Oct. 22 earnings news, which noted that along with raising its 2013 outlook and a 4% increase in third-quarter sales compared with Q3 2012, that the drugmaker “continued to optimize” in certain cost centers. Among them: Sales and Marketing, which accounted for 24.3% of third-quarter sales compared to 24.6% of third-quarter sales in 2012, and by productivity initiatives, such as increasing capacity and shifting production, for around $730 million in savings.

The company-wide assessment also includes talk that Novartis may be interested in spinning off its animal health business. Bloomberg reports that the drugmaker has asked Goldman Sachs to explore a possible deal, but that the company would not confirm the rumor.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.